LYELL IMMUNOPHARMA INC (LYEL)
Health Care · CAR T-cell immunotherapy · NASDAQ
Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility.
What LYELL IMMUNOPHARMA INC does
Lyell Immunopharma is a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous CAR T-cell product candidates for patients with cancer. The company engineers patients' own immune cells and arms them with innovative enhancements, including CAR constructs and manufacturing protocols designed to improve cancer cell killing capabilities. Its lead program, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal trials for relapsed/refractory large B-cell lymphoma, while LYL273, a GCC-targeted CAR T-cell candidate for solid tumors, is in early clinical development. The company also operates the LyFE Manufacturing Center for clinical and commercial CAR T-cell production.
Themes: CAR T-cell immunotherapy, Cell therapy / cellular therapeutics, Hematologic malignancies (large B-cell lymphoma), Solid tumors (colorectal cancer), Cancer immunotherapy, Autologous cell engineering
Fundamentals
- Price$15.53 as of 2026-08-21 close
- Market cap$381M as of 2026-08-21
- 1-year return+45.8% 2025-08-21 close $10.65 → 2026-08-21 close $15.53
- P/En/a negative earnings
- Net margin-794858.1% as of 2026-08-24
- ROE-85.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-52.3% as of 2026-08-24
- Revenue CAGR (3y)-92.5% SEC XBRL
- Beta-0.04 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LYEL compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LYELL IMMUNOPHARMA INC looks technically
LYELL IMMUNOPHARMA INC (LYEL) is trading 24.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 65.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 24.0% below its 200-day average, the long-term trend line — a long-term downtrend | -24.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.69 | $13.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.42 | $20.42 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 15.625. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal | 56 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control | 29.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($12.87 to $17.15) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 62.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.00 | $45.00 |
|---|---|---|
| From the 52-week high | it is 65.5% below its 52-week high (its highest price of the past year) | -65.5% |
| Above the 52-week low | it is 52.4% above its 52-week low (its lowest price of the past year) | +52.4% |
| Below the 52-week high | it is 65.5% below its highest point of the past year | 65.5% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 40 trading days ago | 40 sessions |
| All-time high | its highest closing price on record is $396.80 (set on 2021-09-07) | $396.80 |
| Given back of the 52-week move | over the past year its closes ranged ($10.58 to $38.60), and it has given back almost all of its rise from last year’s low — 82% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.39 to $21.28. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 82.3% |
| From the all-time high | it is 96.1% below its all-time high | -96.1% |
| Nearest price level | it is sitting right on a resistance level at $15.59 — a price it turned at six times since 2025-02-24, most recently on 2026-08-06. Since 2024-08-21 it has 7 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.4% |
| All-time low | its lowest closing price on record is $7.65 (set on 2025-06-02) | $7.65 |
| Above the all-time low | it is 103.0% above its all-time low | +103.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.11 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.17 and $15.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.17 – $14.07 – $15.98 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges below its 200-day average price (24.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 8.9% since the prior reading | -8.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Gap filled | a 4.2% gap up opened on 2026-08-06 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.1 percentage points (the stock gained 18.5% while the market gained 2.3%) | +16.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.3 percentage points (the stock lost 10.2% while the market gained 3.1%) | -13.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 38.5 percentage points (the stock lost 27.4% while the market gained 11.1%) | -38.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 25.3 percentage points (the stock gained 45.8% while the market gained 20.5%) | +25.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 19.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $17.63 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -11.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $14.77 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +5.1% |
Price levels it has turned at before
LYEL last closed at $15.53 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.59 | Resistance | 0.4% above the last close | turned there six times · 2025-02-24 to 2026-08-06 |
| $17.31 | Resistance | 11.4% above the last close | turned there twice · 2024-11-20 to 2026-03-23 |
| $13.71 | Support | 11.7% below the last close | turned there twice · 2025-06-04 to 2025-09-16 |
| $12.64 | Support | 18.6% below the last close | turned there twice · 2025-03-04 to 2025-03-27 |
| $12.41 | Support | 20.1% below the last close | turned there twice · 2025-09-26 to 2026-07-23 |
| $25.32 | Resistance | 63.1% above the last close | turned there twice · 2024-10-17 to 2026-04-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $15.63.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently CUT · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$37.88 range $12.00 – $49.00; median $41.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LYEL
- Consensus EPS estimate-$1.88 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Lead program ronde-cel is in late-stage clinical development with pivotal data expected mid-2027 and BLA submission thereafter; any clinical setback or regulatory delay could materially impact value creation.","Company is unprofitable with significant ongoing R&D and manufacturing costs, limiting cash runway and requiring successful capital raises or commercialization to achieve sustainability.","CAR T-cell therapies face competitive pressure from approved first-generation products (axi-cel, liso-cel) and other next-generation candidates in development by larger biotechnology and pharmaceutical companies."]
What changed in the latest 10-Q
AI-assisted comparison of LYEL's 10-Q filed 2026-05-06 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Annual Report on Form 10-K filed March 12, 2026 (newer filing uses 2025 year-end data)
- Specification that PiNACLE is 'a single-arm clinical trial that is a seamless expansion of the 3L+ cohort in the Phase 1/2 trial'
- Statement that PiNACLE trial 'is expected to report additional data in the second half of 2026 and pivotal data in mid-2027, with submission of a Biologics License Application expected to follow in 2027'
- Description of PiNACLE-H2H as 'first-of-its-kind Phase 3 head-to-head CAR T-cell therapy randomized controlled trial'
- Specification that LYL273 acquisition was 'in November 2025'
- Reference to 'Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics (collectively, ICT)'
- Specification that LYL273 data cutoff date was 'October 28, 2025'
- Statement that LyFE (LyFE Manufacturing Center TM) is 'capable of providing clinical trial material for our ongoing clinical trials, as well as for commercial launch' and 'expect[s] LyFE to have the capacity to manufacture more than 1,200 CAR T-cell doses/year'
- Addition of transformed marginal zone B-cell lymphoma (tMZBCL) and transformed mantle cell lymphoma (tMCL) to NHL subtypes being pursued
- Reference to 'approximately 12,000 to 15,000 patients in the United States with LBC' (text appears truncated)
- Removed:
- Reference to 2024 Annual Report on Form 10-K filed March 11, 2025 (older filing used 2024 year-end data)
- Parenthetical reference '(also known as LYL314)' after rondecabtagene autoleucel in overview section
- Phrase 'chimeric antigen receptor (CAR) T-cell' expanded to 'CAR T-cell' only in newer version
- Phrase 'arm them with one or more of our innovative enhancements' changed to 'arm them with our innovative enhancements'
- Phrase 'delivering patients meaningfully improved outcomes' changed to 'delivering to patients meaningfully improved outcomes'
- Phrase 'CAR T cell products' changed to 'CAR T-cell product candidates'
- Description of PiNACLE as 'a pivotal clinical trial' without 'single-arm' or 'seamless expansion' language
- Reference to 'have announced the initiation of' PiNACLE-H2H (older phrasing)
- Phrase 'recently acquired' changed to specific date reference 'in November 2025'
- Reference to 'Innovative Cellular Therapeutics (ICT)' without mentioning Holdings Limited subsidiary
- Phrase 'refractory metastatic colorectal cancer (mCRC)' changed to 'refractory mCRC'
- Phrase 'in the hostile tumor microenvironment' changed to 'and cancer cell killing in the hostile tumor microenvironment'
- Paragraph describing 'research scientists' developing additional CAR T-cell candidates for solid tumors with anti-exhaustion technologies
- Phrase 'building and operating LyFE' and capacity statements in newer version's incorporated section
- Phrase 'establishing our intellectual property portfolio' changed to 'establishing and maintaining our intellectual property portfolio'
- Parenthetical '(also known as LYL314)' after ronde-cel in Pipeline Programs table heading
- Phrase 'relapsed and/or refractory' changed to 'relapsed/refractory (R/R)'
- Explanation of NHL vs. Hodgkin lymphoma differences in newer version
- Phrase 'The NHL subtypes we intend to initially pursue' changed to 'The NHL subtypes we are currently pursuing'
- Reference to 'tMZBCL and tMCL' added; older version stated 'tFL and Grade 3B follicular lymphoma (FL3B)'
- Phrase 'approximately 12,000 patients' changed to 'approximately 12,000 to 15,000 patients'
- Reworded:
- Change from 'Of the approximately 30,000 patients in the U.S. with LBCL, 40% to 50% are refractory to, or relapse following, first-line treatment and we estimate approximately 12,000 to 15,000 patients in the United States with LBC' (newer, text truncated) vs. older version 'Approximately 40% to 50% of patients with LBCL are refractory to, or relapse following, first-line treatment and we estimate approximately 12,000 patients in the United States with LBCL progress to 2L treatment'
- Shift from reference to 'third- or later-line (3L+) setting' to more detailed description of trial structure and timeline expectations
- Reordering and reorganization of information about LYL273 acquisition timing and clinical data
- Notes:
- Newer filing text appears truncated at end of excerpt ('approximately 12,000 to 15,000 patients in the United States with LBC' is incomplete)
- Older filing excerpt ends at page break; full comparison of subsequent sections not possible
- The removal of the paragraph about 'research scientists' developing additional CAR T-cell candidates may reflect organizational changes or section restructuring rather than substantive removal
Risk Factors
- Added:
- Added bullet point: 'If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed.' (filed 2026-05-06)
- Added bullet point: 'Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.' (filed 2026-05-06)
- Added bullet point: 'If our clinical manufacturing facility in Bothell, Washington or any of our potential contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.' (filed 2026-05-06)
- Added bullet point: 'We do and will continue to or intend to rely on outside scientists and clinical trial investigators and their third-party research institutions for research and development and clinical testing of our product candidates. These scientists, investigators and institutions may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our technologies.' (filed 2026-05-06)
- Added bullet point: 'We are currently in clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates and any product candidates we acquire.' (filed 2026-05-06)
- Removed:
- Removed bullet point: 'We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.' (filed 2025-11-12)
- Removed bullet point: 'We may rely on third parties to manufacture our product candidates, which could subject us to risks and delay or prevent our development and/or commercialization, if approved, of our product candidates.' (filed 2025-11-12)
- Removed bullet point: 'International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and prospects.' (filed 2025-11-12)
- Removed bullet point: 'Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.' (filed 2025-11-12)
- Reworded:
- Reordered bullet points: 'We will require substantial additional capital...' moved from 4th to 2nd position (filed 2026-05-06 vs 2025-11-12)
- Reordered bullet points: 'We operate in a rapidly evolving field...' moved from 2nd to 4th position (filed 2026-05-06 vs 2025-11-12)
- Changed 'Our product candidates and technology platforms' to 'Our product candidates and technologies' (filed 2026-05-06 vs 2025-11-12)
- Changed 'technology platforms' to 'technologies' in related phrase (filed 2026-05-06 vs 2025-11-12)
- Removed phrase 'or finding suitable third-party manufacturing partners' from manufacturing facility bullet (filed 2026-05-06)
- Changed 'The manufacturing of cellular therapies' to 'The manufacturing of cell therapies' (filed 2026-05-06 vs 2025-11-12)
- Removed 'including risks associated with supply chain complexity related to patient materials' from manufacturing risks bullet (filed 2026-05-06)
- Changed 'We face substantial competition in rapidly changing industries' to 'We face substantial competition in a rapidly changing industry' (filed 2026-05-06 vs 2025-11-12)
- Shortened and simplified clinical trial results risk factor; removed phrase 'initial clinical results in a clinical trial may not be predictive of future results in the same clinical trial and results in one indication may not be predictive of results to be expected for the same product candidate in another indication' and 'Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval' (filed 2026-05-06)
- Changed 'Our cellular therapy' to 'Our cell therapy' (filed 2026-05-06 vs 2025-11-12)
- Changed reference from '2025 Annual Report' filed March 11, 2025 to reference to '2025 Annual Report' (filed 2026-05-06 vs 2025-11-12)
- Notes:
- The text provided is truncated at the end of both versions, cutting off the final bullet point about intellectual property protection. Full comparison of that item is not possible.
- Bullet point ordering changes are noted but the substantive content of reordered items remains functionally similar.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 4 sells ($17653) — 4 selling insiders
- Last 90 days0 buys · 7 sells ($42916) — 6 selling insiders
- Last 180 days0 buys · 11 sells ($58500) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LYEL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LYEL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 776,038
- Reported value $15,567,323
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LYEL had 1,231,583 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LYEL had 5.03% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.66 days to cover at the same settlement.
- Reported short interest (shares) 1,231,583
- Short interest (% of shares outstanding) 5.03%
- Prior settlement (shares) 1,220,497
- Reported change 0.91%
- Days to cover (reported) 8.66
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Juno Therapeutics (a Celgene company) - CD19/CD22 CAR T-cell therapies
- Kite Pharma (Gilead subsidiary) - axi-cel (axicabtagene ciloleucel) approved CAR T product
- Celgene / Bristol Myers Squibb - liso-cel (lisocabtagene maraleucel) approved CAR T product
- Bluebird Bio - CAR T and gene therapy programs
- CRISPR Therapeutics - ex vivo CAR T and cell therapy programs
- Allogene Therapeutics - allogeneic CAR T-cell therapies
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LYEL vs…
Frequently asked questions
What does LYELL IMMUNOPHARMA INC (LYEL) do?
Lyell Immunopharma is a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous CAR T-cell product candidates for patients with cancer. The company engineers patients' own immune cells and arms them with innovative enhancements, including CAR constructs and manufacturing protocols designed to improve cancer cell killing capabilities.
What sector is LYELL IMMUNOPHARMA INC (LYEL) in?
LYELL IMMUNOPHARMA INC (LYEL) is classified in the Health Care sector. Its industry is CAR T-cell immunotherapy. It trades on NASDAQ.
Who are LYELL IMMUNOPHARMA INC's (LYEL) competitors?
Notable peers of LYELL IMMUNOPHARMA INC (LYEL) include Juno Therapeutics (a Celgene company) - CD19/CD22 CAR T-cell therapies, Kite Pharma (Gilead subsidiary) - axi-cel (axicabtagene ciloleucel) approved CAR T product, Celgene / Bristol Myers Squibb - liso-cel (lisocabtagene maraleucel) approved CAR T product, Bluebird Bio - CAR T and gene therapy programs and CRISPR Therapeutics - ex vivo CAR T and cell therapy programs. This peer set is informational only — not financial advice.
Is LYELL IMMUNOPHARMA INC (LYEL) overbought or oversold right now?
LYELL IMMUNOPHARMA INC (LYEL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LYEL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.